EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hepatocellular Tumors in Patients With Ornithine Transcarbamylase Deficiency Include Focal Nodular Hyperplasia, Hepatocellular Adenoma, and Hepatocellular Carcinoma

Kelsey (Yiran) Liu, W. Patrick Devine, Soo-Jin Cho, Elizabeth P. Young, Arun Rangaswami, Renata C. Gallagher, Tracy Sirota, Grace E. Kim

Pediatric and Developmental Pathology · 22.11.2026

DOI: 10.1177/10935266261505537 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric and Developmental Pathology, online erschienen am 22.11.2026. Verfasst von Kelsey (Yiran) Liu und 7 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle disorder and can cause potentially life-threatening hyperammonemia. Hepatocellular carcinoma (HCC) and hepatocellular adenoma (HCA) have been reported in OTCD, usually in adults. Non-neoplastic histologic findings include non-specific glycogenosis, steatosis, and fibrosis.

Design

A retrospective pathology database search between 2000 and 2024 was performed to identify patients with a clinical history of OTCD. Electronic medical records were reviewed for clinical, laboratory, genetic, and imaging findings. Available native liver specimens underwent histologic review, with additional studies performed in select cases.

Results

We identified 11 patients with OTCD. All patients were diagnosed biochemically; pathogenic OTC mutations were detected in all 8 tested patients. Three patients had hepatocellular lesions. One patient with Li-Fraumeni syndrome developed focal nodular hyperplasia (FNH) at age 6 and conventional HCC at age 10, when OTCD was also diagnosed. RNA sequencing revealed biased allelic expression toward the mutant OTC allele in the FNH (100% mutant), HCC (94% mutant), and background liver (87% mutant). Two additional pediatric patients had incidental HCAs identified on explant examination at 9 and 17 years of age. The remaining 8 patients (72%) had no focal hepatic lesions. Glycogenosis was the most common histologic finding (10/11, 91%). Only 1 patient had significant steatosis (grade 2) or fibrosis (stage 1).

Conclusion

Hepatocellular tumors in OTCD included HCC, HCA, and FNH in pediatric patients. Glycogenosis was the predominant non-neoplastic histologic finding. These findings expand the spectrum of hepatic lesions and non-neoplastic liver pathology reported in OTCD.

Zitieren

APA

Liu, K. Y., Devine, W. P., Cho, S., Young, E. P., Rangaswami, A., Gallagher, R. C., Sirota, T., & Kim, G. E. (2026). Hepatocellular Tumors in Patients With Ornithine Transcarbamylase Deficiency Include Focal Nodular Hyperplasia, Hepatocellular Adenoma, and Hepatocellular Carcinoma. Pediatric and Developmental Pathology. https://doi.org/10.1177/10935266261505537

Vancouver

Liu KY, Devine WP, Cho S, Young EP, Rangaswami A, Gallagher RC, et al. Hepatocellular Tumors in Patients With Ornithine Transcarbamylase Deficiency Include Focal Nodular Hyperplasia, Hepatocellular Adenoma, and Hepatocellular Carcinoma. Pediatric and Developmental Pathology. 2026. doi:10.1177/10935266261505537

BibTeX
@article{Liu2026,
  author = {Liu, Kelsey (Yiran) and Devine, W. Patrick and Cho, Soo-Jin and Young, Elizabeth P. and Rangaswami, Arun and Gallagher, Renata C. and Sirota, Tracy and Kim, Grace E.},
  title = {Hepatocellular Tumors in Patients With Ornithine Transcarbamylase Deficiency Include Focal Nodular Hyperplasia, Hepatocellular Adenoma, and Hepatocellular Carcinoma},
  journal = {Pediatric and Developmental Pathology},
  year = {2026},
  doi = {10.1177/10935266261505537}
}
Kostenlos starten →